Last reviewed · How we verify
intravenous glucose tolerance test
At a glance
| Generic name | intravenous glucose tolerance test |
|---|---|
| Also known as | ivGTT |
| Sponsor | German Diabetes Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test (PHASE1)
- Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency (NA)
- Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET (NA)
- Arginine Metabolism in Youth With Type 2 Diabetes (NA)
- Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous glucose tolerance test CI brief — competitive landscape report
- intravenous glucose tolerance test updates RSS · CI watch RSS
- German Diabetes Center portfolio CI